A. Khemis, A. Kaiafa, C. Queille-Roussel, L. Duteil, J. P. Ortonne (2007-5). “Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial”. The British journal of dermatology156 (5): 997–1004. doi:10.1111/j.1365-2133.2007.07814.x. PMID17388924.
Sun Young Huh, Jung-Won Shin, Jung-Im Na, Chang-Hun Huh et al. (2010-4). “Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial”. The Journal of dermatology37 (4): 311–315. doi:10.1111/j.1346-8138.2010.00787.x. PMID20507399.
Francesca Romana Grippaudo, Pier Paolo Di Russo (2016-12). “Effects of topical application of B-Resorcinol and Glycyrrhetinic acid monotherapy and in combination with fractional CO2 laser treatment for benign hand hyperpigmentation treatment”. Journal of cosmetic dermatology15 (4): 413–419. doi:10.1111/jocd.12241. PMID27325103.
Suyong Kim, Huisuk Yang, Miroo Kim, Ji Hwoon Baek et al. (2016-3). “4-n-butylresorcinol dissolving microneedle patch for skin depigmentation: a randomized, double-blind, placebo-controlled trial”. Journal of cosmetic dermatology15 (1): 16–23. doi:10.1111/jocd.12178. PMID26341915.
Frank Dreher, Zoe D. Draelos, Michael H. Gold et al. (2013-3). “Efficacy of hydroquinone-free skin-lightening cream for photoaging”. Journal of cosmetic dermatology12 (1): 12–17. doi:10.1111/jocd.12025. PMID23438137.
Michael H. Gold, Julie Biron (2011-9). “Efficacy of a novel hydroquinone-free skin-brightening cream in patients with melasma”. Journal of cosmetic dermatology10 (3): 189–196. doi:10.1111/j.1473-2165.2011.00573.x. PMID21896130.
A. Khemis, A. Kaiafa, C. Queille-Roussel, L. Duteil, J. P. Ortonne (2007-5). “Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial”. The British journal of dermatology156 (5): 997–1004. doi:10.1111/j.1365-2133.2007.07814.x. PMID17388924.
Sun Young Huh, Jung-Won Shin, Jung-Im Na, Chang-Hun Huh et al. (2010-4). “Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial”. The Journal of dermatology37 (4): 311–315. doi:10.1111/j.1346-8138.2010.00787.x. PMID20507399.
Francesca Romana Grippaudo, Pier Paolo Di Russo (2016-12). “Effects of topical application of B-Resorcinol and Glycyrrhetinic acid monotherapy and in combination with fractional CO2 laser treatment for benign hand hyperpigmentation treatment”. Journal of cosmetic dermatology15 (4): 413–419. doi:10.1111/jocd.12241. PMID27325103.
Suyong Kim, Huisuk Yang, Miroo Kim, Ji Hwoon Baek et al. (2016-3). “4-n-butylresorcinol dissolving microneedle patch for skin depigmentation: a randomized, double-blind, placebo-controlled trial”. Journal of cosmetic dermatology15 (1): 16–23. doi:10.1111/jocd.12178. PMID26341915.
Frank Dreher, Zoe D. Draelos, Michael H. Gold et al. (2013-3). “Efficacy of hydroquinone-free skin-lightening cream for photoaging”. Journal of cosmetic dermatology12 (1): 12–17. doi:10.1111/jocd.12025. PMID23438137.
Michael H. Gold, Julie Biron (2011-9). “Efficacy of a novel hydroquinone-free skin-brightening cream in patients with melasma”. Journal of cosmetic dermatology10 (3): 189–196. doi:10.1111/j.1473-2165.2011.00573.x. PMID21896130.